Alnylam Licenses RNAi Patents to Invitrogen, Cell Signaling Technology, Cenix | GenomeWeb

NEW YORK, Jan. 13 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed RNA interference patents to Invitrogen, Cell Signaling Technology, and Cenix Bioscience, the company said today.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.